US Edition
The Evolution of SGLT2 Inhibitors: From Apple Tree Bark to Clinical Impacts Beyond Glycemic Control
Summary by Drug Hunter
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The Evolution of SGLT2 Inhibitors: From Apple Tree Bark to Clinical Impacts Beyond Glycemic Control
Inhibition of SGLT2 with small molecules has emerged as one of the most successful strategies to date managing T2DM. Beyond glycemic control, SGLT2 inhibitors have demonstrated unexpected and transformative benefits in cardiovascular and renal diseases, among others. In this review, we explore the therapeutic hypothesis behind SGLT2 inhibition, the natural product origins of the drug class, key efficacy findings across large clinical trials, and…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium